Skip to main content
icon for Skin cancer vaccine BLA submitted by June 30, 2027?
Teknologi·FDA

Skin cancer vaccine BLA submitted by June 30, 2027?

icon for Skin cancer vaccine BLA submitted by June 30, 2027?
Teknologi·FDA

Skin cancer vaccine BLA submitted by June 30, 2027?

88% peluang
Polymarket

$38,832 Vol.

88% peluang
Polymarket

$38,832 Vol.

This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No". Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program. A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication. A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof. The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify. If the FDA grants approval of intismeran autogene on or before June 30, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed. The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.Recent positive Phase 3 results from the INTerpath-001 trial of intismeran autogene (mRNA-4157), the personalized mRNA neoantigen therapy developed by Moderna and Merck, represent the key driver behind the 87.5% market-implied odds. The August 19 announcement showed statistically significant gains in recurrence-free and distant metastasis-free survival versus Keytruda alone in resected high-risk melanoma, prompting immediate plans to share full data at a medical conference and engage regulators on filing. Combined with the therapy’s breakthrough designation, five-year Phase 2 durability data from earlier 2026, and typical BLA preparation timelines after such readouts, traders see strong momentum toward submission well before the June 2027 cutoff. Key near-term catalysts include the data presentation and any accelerated review signals from the FDA.

This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No".

Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.

A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication.

A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof.

The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify.

If the FDA grants approval of intismeran autogene on or before June 30, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed.

The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.
Volume
$38,832
Tanggal Berakhir
Jun 30, 2027
Pasar Dibuka
Aug 19, 2026, 2:46 PM ET

Resolver

0x65070BE91...
This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No". Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program. A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication. A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof. The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify. If the FDA grants approval of intismeran autogene on or before June 30, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed. The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.
This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No". Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program. A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication. A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof. The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify. If the FDA grants approval of intismeran autogene on or before June 30, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed. The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.Recent positive Phase 3 results from the INTerpath-001 trial of intismeran autogene (mRNA-4157), the personalized mRNA neoantigen therapy developed by Moderna and Merck, represent the key driver behind the 87.5% market-implied odds. The August 19 announcement showed statistically significant gains in recurrence-free and distant metastasis-free survival versus Keytruda alone in resected high-risk melanoma, prompting immediate plans to share full data at a medical conference and engage regulators on filing. Combined with the therapy’s breakthrough designation, five-year Phase 2 durability data from earlier 2026, and typical BLA preparation timelines after such readouts, traders see strong momentum toward submission well before the June 2027 cutoff. Key near-term catalysts include the data presentation and any accelerated review signals from the FDA.

This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No".

Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.

A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication.

A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof.

The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify.

If the FDA grants approval of intismeran autogene on or before June 30, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed.

The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.
Volume
$38,832
Tanggal Berakhir
Jun 30, 2027
Pasar Dibuka
Aug 19, 2026, 2:46 PM ET

Resolver

0x65070BE91...
This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No". Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program. A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication. A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof. The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify. If the FDA grants approval of intismeran autogene on or before June 30, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed. The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.

Terkait

icon for Skin cancer vaccine FDA approved by December 31, 2027?

Skin cancer vaccine FDA approved by December 31, 2027?

68%
icon for Merck & Moderna merger/acquisition announced in 2026?

Merck & Moderna merger/acquisition announced in 2026?

2%
icon for Apakah FDA menyetujui Retatrutide tahun ini?

Apakah FDA menyetujui Retatrutide tahun ini?

3%
Ya

Hati-hati dengan link eksternal.

Pertanyaan yang Sering Diajukan

"Skin cancer vaccine BLA submitted by June 30, 2027?" adalah pasar prediksi di Polymarket di mana trader membeli dan menjual saham "Ya" atau "Tidak" berdasarkan apakah mereka yakin event ini akan terjadi. Probabilitas crowd-sourced saat ini adalah 88% untuk "Yes." Misalnya, jika "Ya" dihargai 88¢, pasar secara kolektif memberikan peluang 88% bahwa event ini akan terjadi. Peluang ini bergeser terus-menerus saat trader bereaksi terhadap perkembangan dan informasi baru. Saham dengan hasil yang benar bisa ditukarkan seharga $1 setiap saham saat pasar diselesaikan.

Per hari ini, "Skin cancer vaccine BLA submitted by June 30, 2027?" telah menghasilkan $38.8K dalam total volume trading sejak pasar diluncurkan pada Aug 19, 2026. Tingkat aktivitas trading ini mencerminkan keterlibatan kuat dari komunitas Polymarket dan membantu memastikan bahwa peluang saat ini diinformasikan oleh kumpulan besar peserta pasar. Kamu bisa melacak pergerakan harga langsung dan trading di hasil apa pun langsung di halaman ini.

Untuk trading di "Skin cancer vaccine BLA submitted by June 30, 2027?," cukup pilih apakah kamu yakin jawabannya "Ya" atau "Tidak." Setiap sisi memiliki harga saat ini yang mencerminkan probabilitas tersirat pasar. Masukkan jumlah kamu dan klik "Trade." Jika kamu membeli saham "Ya" dan hasilnya diselesaikan sebagai "Ya," setiap saham membayar $1. Jika diselesaikan sebagai "Tidak," saham "Ya" kamu bernilai $0. Kamu juga bisa menjual sahammu kapan saja sebelum resolusi jika kamu ingin mengamankan keuntungan atau memotong kerugian.

Probabilitas saat ini untuk "Skin cancer vaccine BLA submitted by June 30, 2027?" adalah 88% untuk "Yes." Ini berarti keramaian Polymarket saat ini percaya ada peluang 88% bahwa event ini akan terjadi. Peluang ini diperbarui secara real-time berdasarkan trade aktual, memberikan sinyal yang terus diperbarui tentang apa yang diharapkan pasar.

Aturan resolusi untuk "Skin cancer vaccine BLA submitted by June 30, 2027?" mendefinisikan dengan tepat apa yang harus terjadi agar setiap hasil dinyatakan sebagai pemenang — termasuk sumber data resmi yang digunakan untuk menentukan hasilnya. Kamu bisa meninjau kriteria resolusi lengkap di bagian "Aturan" di halaman ini di atas komentar. Kami menyarankan membaca aturan dengan cermat sebelum trading, karena mereka menentukan kondisi tepat, kasus khusus, dan sumber yang mengatur bagaimana pasar ini diselesaikan.